NEXAVAR® (sorafenib) provides proven OS benefit in patients with uHCC1

NEXAVAR significantly extended OS vs placebo in the SHARP clinical trial1

Median OS in SHARP trial1
Median overall survival data for NEXAVAR® (sorafenib)

NEXAVAR extended survival by

44%

HR: 0.69; 95% Cl, 0.55-0.87; P=0.00058

  • 31% reduction in risk of death with NEXAVAR1

SHARP (Sorafenib HCC Assessment Randomized Protocol): A randomized, double-blind, placebo-controlled, international, multicenter trial in patients with unresectable HCC (N=602).1

NEXAVAR extended survival by

44%

HR: 0.69; 95% Cl, 0.55-0.87; P=0.00058

SHARP (Sorafenib HCC Assessment Randomized Protocol): A randomized, double-blind, placebo-controlled, international, multicenter trial in patients with unresectable HCC (N=602).1

View the SHARP trial publication by Llovet et al in N Engl J Med.

OS advantage of NEXAVAR demonstrated across patient subsets analyzed in the SHARP pivotal trial

OS of selected groups, according to baseline prognostic factors2
Overall survival data in selected groups
The OS advantage of NEXAVAR was consistent across all patient subsets analyzed1

The trial was not powered to assess differential patient response to treatment by subsets, and no adjustments were made for multiple comparisons. The univariate, exploratory subset analyses were intended to be descriptive only. Therefore, the results of these descriptive analyses cannot be used to conclude whether a real difference in treatment effect exists between subsets.3